Company Overview of Oryzon Genomics S.A.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies to treat oncology and neurodegenerative diseases. Its clinical-stage product candidates include ORY-1001, an oncology product, which is in Phase I/IIA clinical trial for treating acute leukemia disease; and ORY-2001, a dual selective LSD1 and MAO-B inhibitor that is in Phase I clinical trial for Alzheimer and other diseases. The company has collaboration agreement with ROCHE for the development of its product, ORY-1001. Oryzon Genomics S.A. was founded in 2000 and is headquartered in Barcelona, Spain.
Sant Ferran 74
Cornella de Llobregat
Founded in 2000
34 93 515 13 13
34 93 377 40 28
Key Executives for Oryzon Genomics S.A.
Oryzon Genomics S.A. Key Developments
Similar Private Companies By Industry
|A.S.A.C. Pharmaceutical I.A.E.||Europe|
|ABAC Therapeutics SA||Europe|
|Advanced In Vitro Cell Technologies S.A.||Europe|
|Advanced Marker Discovery, S.L.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Oryzon Genomics S.A., please visit www.oryzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.